Cary Street Partners Investment Advisory LLC Bluebird Bio, Inc. Transaction History

Cary Street Partners Investment Advisory LLC

$2.63 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2023 Aug 10, 2023	BUY	$2.79 - $5.03 $4,185 - $7,545	1,500 Added 1428.57%	1,605 $5,000
Q4 2022 Feb 14, 2023	BUY	$5.77 - $8.49 $605 - $891	105 New	105 $0

Others Institutions Holding BLUE

# of Institutions

151

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

Black Rock Inc. New York, NY

15.4M
Shares

$5.71 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.5M
Shares

$3.88 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

4.68M
Shares

$1.73 Million
0.0% of portfolio
Pictet Asset Management Sa Geneva 73, V8

4.67M
Shares

$1.73 Million
0.02% of portfolio
State Street Corp Boston, MA

3.84M
Shares

$1.42 Million
0.0% of portfolio

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cary Street Partners Investment Advisory LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cary Street Partners Investment Advisory LLC with notifications on news.

Account